乙基葡糖苷 | 30285-48-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 乙基葡糖苷
• 英文名称: Ethyl glucoside
• 英文别名: 2-ethoxy-6-(hydroxymethyl)oxane-3,4,5-triol
• CAS: 30285-48-4
• 化学式: C₈H₁₆O₆
• 分子量: 208.21
• InChiKey: WYUFTYLVLQZQNH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.8
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  99.4
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• [EN] CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS ANTISENS CONJUGUÉS ET LEUR UTILISATION
  申请人：ISIS PHARMACEUTICALS INC

  公开号：WO2014179620A1

  公开（公告）日：2014-11-06

  Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.

  本文提供了具有共轭基团的寡聚化合物。在某些实施例中，这些寡聚化合物与N-乙酰半乳糖结合。
• BRANCHED POLYALKYLENE GLYCOLS
  申请人：Yamasaki Motoo

  公开号：US20080125350A1

  公开（公告）日：2008-05-29

  The present invention provides a branched polyalkylene glycol wherein three or more single-chain polyalkylene glycols and a group having reactivity with an amino acid side chain, the N-terminal amino group or the C-terminal carboxyl group in a polypeptide or a group convertible into the group having reactivity are bound; and a physiologically active polypeptide modified with the branched polyalkylene glycol.

  本发明提供了一种分支状聚烷基乙二醇，其中三个或更多单链聚烷基乙二醇和一个具有与多肽中氨基酸侧链、N-末端氨基基团或C-末端羧基基团反应性的基团，或可转化为具有反应性基团的基团，被结合；以及经过分支状聚烷基乙二醇修饰的生理活性多肽。
• NEUROKININ-1 ANTAGONIST
  申请人：Shanghai Shengdi Pharmaceutical Co., Ltd

  公开号：EP3991730A1

  公开（公告）日：2022-05-04

  A compound represented by formula II or a pharmaceutically acceptable salt thereof, and a preparation method therefor. The compound represented by formula II is an antagonist of a neurokinin-1 receptor, can be used for treating diseases related to the neurokinin-1 receptor, and can avoid hemolytic effects of drugs and reduce the side effects of drug administration.

  化合物II或其药学上可接受的盐的代表，以及其制备方法。化合物II是神经激肽-1受体的拮抗剂，可用于治疗与神经激肽-1受体相关的疾病，并可以避免药物的溶血作用并减少药物治疗的副作用。
• Compositions and methods for modulating complement factor B expression
  申请人：Ionis Pharmaceuticals, Inc.

  公开号：US10280423B2

  公开（公告）日：2019-05-07

  The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with dysregulation of the complement alternative pathway by administering a Complement Factor B (CFB) specific inhibitor to a subject.

  本发明的实施方案提供了通过向受试者施用补体因子B（CFB）特异性抑制剂来治疗、预防或改善与补体替代途径失调相关的疾病的方法、化合物和组合物。
• Orally available compounds, a process for preparing the same and their uses as anti-adhesive drugs for treating E. coli induced inflammatory bowel diseases such as crohn's disease
  申请人：CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

  公开号：US10632135B2

  公开（公告）日：2020-04-28

  Orally available compounds, a process for preparing the same and their uses as anti-adhesive drugs for treating E. coli induced inflammatory bowel diseases such as crohn's disease.

  可口服的化合物、制备相同化合物的工艺及其作为治疗大肠杆菌诱发的炎症性肠病（如羊角风病）的抗粘连药物的用途。

表征谱图